Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of California, San Francisco
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Plexxikon
Eisai Inc.
Information provided by (Responsible Party):
Hope Rugo, MD, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01596751
First received: May 7, 2012
Last updated: August 15, 2014
Last verified: August 2014

May 7, 2012
August 15, 2014
July 2012
January 2015   (final data collection date for primary outcome measure)
  • Maximum tolerated dose of PLX3397 given in combination with with standard dose eribulin in patients with metastatic breast cancer (Phase 1b) [ Time Frame: Estimated up to 24 months ] [ Designated as safety issue: Yes ]
  • Percentage of patients with chemotherapy pre-treated triple negative metastatic breast cancer treated with PLX3397 in combination with eribulin who are progression free at 12 weeks (Phase 2) [ Time Frame: Evaluated at week 12 tumor assessment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01596751 on ClinicalTrials.gov Archive Site
  • Serum concentrations for the combination of PLX3397 and eribulin (Phase 1b) [ Time Frame: Up to 42 days. ] [ Designated as safety issue: No ]
  • Safety of treatment (Phase 1b & 2) [ Time Frame: Approximately 24 months ] [ Designated as safety issue: Yes ]
    AE and toxicity assessments (laboratory tests, physical exams & history) on Days 1 and Day 8 of each cycle during treatment
  • Immune response (Phase 1b & 2) [ Time Frame: Up to 42 days. ] [ Designated as safety issue: No ]
  • Efficacy of drug combination including response rate and duration of response (Phase 2) [ Time Frame: Participants will be assessed every 3 weeks and have CT scans every 6 weeks during treatment. Average participation is approximately 24 months. ] [ Designated as safety issue: No ]
  • Serum concentrations for the combination of PLX3397 and eribulin (Phase 1b) [ Time Frame: Up to 42 days. ] [ Designated as safety issue: No ]
  • Safety of treatment (Phase 1b & 2) [ Time Frame: AE and toxicity assessments Days 1 and Day 8 of each cycle during treatment. Average participation is approximately 24 months. ] [ Designated as safety issue: Yes ]
  • Immune response (Phase 1b & 2) [ Time Frame: Up to 42 days. ] [ Designated as safety issue: No ]
  • Efficacy of drug combination including response rate and duration of response (Phase 2) [ Time Frame: Participants will be assessed every 3 weeks and have CT scans every 6 weeks during treatment. Average participation is approximately 24 months. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.

This is a nonrandomized, open label phase Ib/II study evaluating the safety and efficacy of eribulin in combination with PLX3397, a novel CSF1 inhibitor, in patients with metastatic breast cancer. The phase II portion of this trial will be limited to patients with triple negative disease.

The phase I portion of this trial is a dose escalation of PLX3397 to determine the maximum tolerated dose (MTD) of PLX3397 when given in combination with standard dose eribulin. Patients will be enrolled in cohorts of three, using the dose levels and plan outlined in the statistical section, with 6 patients enrolled at the MTD. All patients with accessible tumor will be required to have a tumor biopsy at study start before starting therapy. Pharmacokinetics of PLX3397 and eribulin, and blood levels of CSF1 will be obtained as outlined in section 14. To allow rapid accrual to phase Ib, and an earlier start to the phase II trial, patients will be enrolled in phase I with both hormone receptor positive and negative disease, and at any line of therapy assuming eligibility criteria are otherwise met.

Dose limiting toxicity (DLT) will be defined as any treatment-related toxicity meeting the criteria below and occurring within the first 21 days of combination therapy. Patients must receive at least 14 days of PLX3397 and 2 doses of eribulin during the first cycle in order to be considered evaluable for DLT (unless the missed doses are due to a DLT).

Patients in each cohort will be followed for at least 3 weeks (one full cycle) before opening accrual to the next dose level. If one patient in any cohort develops a DLT, an additional 3 patients will be enrolled at that level. If no additional toxicities occur in the six patients, then this particular dose would be used for the phase II trial, and the next higher dose would be considered the MTD. A minimum of 12 and maximum of 24 patients will be enrolled in the phase I study. The phase II trial will not open until the last patient in the phase I study has been followed for at least 3 weeks.

The phase II portion of this trial will evaluate PFS in patients with TNBC treated with PLX3397 and eribulin, using the dose of PLX3397 determined in the phase Ib study in a two-step design. Please see the statistical section for details regarding enrollment and statistical design. Treatment is preceded by a 5 to 7 day lead-in phase, in which patients will take PLX3397 alone daily. Patients with accessible tumor will undergo a core biopsy of tumor before the start of PLX3397 treatment, and then a fine needle aspiration or core biopsy will be performed on the day of or the day before the start of eribulin (day -1 to day 0).

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Breast Cancer
  • Drug: PLX3397
    Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
  • Drug: Eribulin
    Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
    Other Names:
    • Halaven
    • E7389
Experimental: Eribulin in combination with PLX3397

Phase Ib:

21 day treatment cycle: PLX3397 100-200 mg gelcaps, po daily & Eribulin 1.4 mg/m2 IV day 1 and 8

  • Cohort 1: 600 mg/day
  • Cohort 2: 800 mg/day
  • Cohort 3: 1000 mg/day

Phase II:

Lead in period of 5-7 d with PLX3397 at MTD po qd (day -7/5 to day 0)

21 day cycles; Day 1:

  • Add eribulin 1.4 mg/m2 IV day 1 and 8
  • Continue PLX3397 at MTD po qd
Interventions:
  • Drug: PLX3397
  • Drug: Eribulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
January 2016
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically confirmed diagnosis of breast cancer with documented progressive disease.
  • Patients with stable brain metastases are eligible for this trial.
  • At least one prior chemotherapy regimen for metastatic breast cancer. Prior treatment must be discontinued at least 2 weeks before treatment start.
  • Concomitant therapy with bisphosphonates is allowed.
  • Stable dose coumadin anticoagulation is allowed, providing that anticoagulation can be safely held to an INR within normal range for the purpose of tumor biopsy. LMWH is the preferred method of anticoagulation.
  • PT/INR and PTT within institutional normal limits within two weeks before initial biopsy.
  • Measurable disease, as defined by RECIST guidelines or evaluable disease. Bone metastases must be evaluable.
  • Disease amenable to core biopsy. Patients with pulmonary metastases as their only site of disease may enroll on this trial and will not undergo biopsy.
  • For Phase I: patients with HER2 overexpressing disease must have been previously treated with trastuzumab. Patients with HER2 overexpressing disease are not eligible for the Phase II trial.
  • Age eighteen years or older.
  • ECOG performance status </= 2.
  • Life expectancy of >/= 12 weeks.
  • Patients with < grade 1 peripheral neuropathy are eligible for this trial.
  • Adequate bone marrow reserve: ANC >/= 1000, platelets >/= 100,000.
  • Adequate renal function: serum creatinine </= 1.5x upper limit of normal OR calculated creatinine clearance ≥ 50 ml/min.
  • Sodium, potassium, and chloride levels within institutional normal limits.
  • Adequate hepatic function: AST and ALT </= 2.5 x ULN, and total bilirubin </= 1.5x upper limit of normal. In patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be </= 5 times the ULN.
  • At baseline: EF ≥ 50%, no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point - patients may be eligible for study if the drug can be changed to another agent with less risk (such as changing from citalopram to an alternate antidepressant).
  • Able to take oral medications and maintain hydration.
  • Ability to give written informed consent and willingness to comply with the requirements of the protocol
  • Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drug

Specific inclusion criteria for Phase II

• Patients enrolling on the phase II portion of this trial must have ER, PR and HER2 negative disease defined as less than 10% staining for ER and PR, and HER2 not amplified by FISH, 0-1% by IHC, or 2+ by IHC and no evidence of amplification by FISH.

Exclusion Criteria:

  • Treatment with another chemotherapy or hormonal therapy within the past 2 weeks.
  • Treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks.
  • Concurrent treatment with radiotherapy.
  • Ongoing treatment with any other investigational therapy.
  • Prior treatment with eribulin
  • Severe, concurrent illness including congestive heart failure, significant cardiac disease and uncontrolled hypertension, that would likely prevent the patient from being able to comply with the study protocol.
  • Inadequate bone marrow, renal, or hepatic function as defined above, or an active coagulopathy that precludes tissue biopsy.
  • Pregnant or lactating women and women of child-bearing potential who are not using an effective method of birth control. Women of childbearing potential must undergo a serum pregnancy test within seven days of starting the study drug.
Both
18 Years and older
No
Contact: Hope S. Rugo, MD 415-353-7428 hrugo@medicine.ucsf.edu
United States
 
NCT01596751
UCSF Protocol No. 12751
Yes
Hope Rugo, MD, University of California, San Francisco
Hope Rugo, MD
  • Susan G. Komen Breast Cancer Foundation
  • Plexxikon
  • Eisai Inc.
Study Chair: Hope S. Rugo, MD University of California, San Francisco
University of California, San Francisco
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP